Studies tumor samples to guide future cancer treatment choices
Looks at stored tumor samples from adults with several cancers to find markers.
Plain-language title generated from the registry record
Registry title: Ontario-wide Cancer TArgeted Nucleic Acid Evaluation
Key facts
- Where
- Hamilton, Kingston, London, Ottawa, and Toronto, CanadaSee the 7 sites
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with advanced solid tumours who are candidates for systemic therapy and have stored tumour tissue for gene testing.
- Age
- 18 years or older
- Sex
- All sexes
- Disease stage
- Advanced solid tumour cancer confirmed by tissue examination; candidates for systemic therapy
- Earlier treatment
- Cannot have had more than 2 lines of earlier cytotoxic therapy for recurrent or metastatic disease. This limit does not apply to Phase I trial candidates.
- Biomarker or test result
- Enough stored (FFPE archived) tumour tissue for molecular profiling
Main reasons for not taking part
- More than 2 lines of prior cytotoxic therapy for recurrent or metastatic disease (not applied to Phase I trial candidates)
Read by machine on 9 November 2026.
Where in Canada
- Juravinski Cancer CentreHamilton, CanadaNo longer taking part
- Kingston General HospitalKingston, CanadaNo longer taking part
- London Health Sciences CentreLondon, CanadaNo longer taking part
- The Ottawa Hospital Cancer CentreOttawa, CanadaTaking people
- Princess Margaret HospitalToronto, CanadaTaking people
- Mount Sinai HospitalToronto, CanadaNo longer taking part
- Sunnybrook Health Sciences CentreToronto, CanadaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University Health Network, Toronto
- Trial code
- NCT02906943
- Record updated
- 5 June 2026
- Original description
Substantial progress has been made in the treatment of cancer through the use of targeted therapies, but what works for one patient might not work for another patient. Certain drugs are now being developed that target specific molecules in the body that are believed to be part of the disease.Read full original descriptionShow less
Ontario-wide Cancer TArgeted Nucleic Acid Evaluation
Substantial progress has been made in the treatment of cancer through the use of targeted therapies, but what works for one patient might not work for another patient. Certain drugs are now being developed that target specific molecules in the body that are believed to be part of the disease.
Biomarkers are specific characteristics of the cancer that may help provide prognostic information (e.g. how well patients will be regardless of the treatments given) or help predict sensitivity or resistance to a specific treatment.
The study will collect archival tumor samples (previously collected biopsy or surgical tumor samples) to provide biomarker data about a patient's cancer, which may help their physicians to identify which clinical trials of new drug treatments may be most appropriate for the patient in the future and may also guide the use of approved treatments that may potentially benefit the patient.
Another goal of this study is to develop a province-wide registry of targeted gene sequencing testing results that will be made available to cancer researchers. Additional tumour tissue and blood samples collected from all study participants will also be stored in a biobank at the Ontario Institute for Cancer Research for future research.
The study will also look at linking data from this study to other health care databases to further collect information about the health care the patients received, including medical tests, clinic visits, or procedures both before and after participating in this study. Having more information about patient health to relate to the DNA sequences may provide new insights into cancer and its treatment.
Inclusion: Patients with histological confirmation of advanced solid tumor malignancies who are candidates for systemic therapy; All patients must have sufficient FFPE archived tumor tissue for molecular profiling; Patient must be ≥ 18 years old; Patient's ECOG performance status equal to 0 or 1; All patients must have a life expectancy of > 6 months; All patients must have adequate organ functions; All patients must have signed and dated an informed consent form.
Exclusion: Patients must not have received more than 2 lines of prior cytotoxic therapy for their recurrent/metastatic disease, with the exception of Phase I trial candidates who will not be excluded if more than 2 lines of prior cytotoxic therapy have been received.